新型CRISPR-Cas12M酶和系统
By developing novel RNA-guided endonucleases and CRISPR/Cas systems, the shortcomings of existing CRISPR/Cas systems have been addressed, resulting in more robust gene editing effects and improved accuracy and efficiency in target sequence cutting.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CHINA AGRI UNIV
- Filing Date
- 2020-06-29
- Publication Date
- 2026-07-17
AI Technical Summary
Existing CRISPR/Cas systems each have their own advantages and disadvantages in gene editing, and there is a need to develop a more robust new CRISPR/Cas system with good performance in many aspects.
A novel RNA-guided endonuclease was developed, and a new CRISPR/Cas system and its gene editing method were constructed based on this enzyme. These include proteins, conjugates, fusion proteins, and complexes, which are prepared by genetic engineering or chemical synthesis methods and are used to cleave target sequences at specific sites by binding to guide RNA.
It achieves more robust gene editing results, improves the accuracy and efficiency of target sequence cutting, reduces off-target effects, and expands the application potential of gene editing.
Smart Images
Figure BDA0002560901440000281 
Figure BDA0002560901440000291 
Figure BDA0002560901440000301